Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Clinical Development of Regorafenib Combinations in Pediatric Rhabdomyosarcoma

November 27th 2018

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the clinical development of regorafenib (Stivarga) combinations in pediatric rhabdomyosarcoma.

FDA Approves Larotrectinib for NTRK+ Cancers

November 27th 2018

The FDA has approved larotrectinib for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an NTRK gene fusion.

Dr. Link on Evolution of Treatment in Pediatric Cancer

November 22nd 2018

Michael Link, MD, professor of pediatrics, Stanford Cancer Institute, 2018 Giant of Cancer Care in Pediatrics, discusses the evolution of treatment in pediatric cancer.

Cognitive Outcomes Improved With Proton Therapy in Pediatric Brain Tumors

November 19th 2018

Favorable neurocognitive outcomes were observed in pediatric patients with brain tumors with the use of proton radiation therapy compared with X-ray radiation therapy.

Dr. Chi on Tazemetostat in Pediatric Patients With INI1-Negative Tumors

November 17th 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the EZH2 inhibitor tazemetostat in pediatric patients with INI1-negative tumors.

Dr. Upadhyaya on the Importance of Long-Term Follow-Up in Pediatric Patients With Ependymoma

November 16th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the importance of long-term follow-up in pediatric patients with ependymoma.

Dr. Lassen Discusses TRK Fusions in Pediatric Patients

November 14th 2018

Ulrik Lassen, MD, PhD, head of the Phase I Unit at Rigshospitalet, discusses TRK fusions in pediatric patients with cancer.

Rationale for Regorafenib Combination Study in Pediatric Rhabdomyosarcoma

November 9th 2018

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the rationale for a study of regorafenib (Stivarga) combinations in pediatric patients with rhabdomyosarcomas (RMS).

Identifying the Risk of Breast Cancer in Childhood Cancer Survivors

November 7th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a study that is identifying the risk of breast cancer in survivors of childhood cancer.

Dr. Hamid on the Effectiveness of Immunotherapy in AYA Patients With Melanoma

November 3rd 2018

Omid Hamid, MD, director of Research and Immuno-Oncology at The Angeles Clinic, discusses the effectiveness of immunotherapy in adolescent and young adult (AYA) patients with melanoma.

Optimal Regorafenib Combinations in Pediatric Rhabdomyosarcomas

November 2nd 2018

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the optimal partner for regorafenib (Stivarga) in pediatric rhabdomyosarcomas.

Novel Combination Explored in Pediatric Rhabdomyosarcoma

November 1st 2018

Dieter Zopf discusses the identification of effective drug combinations with regorafenib for the treatment of patients with pediatric rhabdomyosarcomas.

Dr. Tasian on the Heterogeneity of Ph-Like ALL in Pediatric Patients

October 29th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the heterogeneity of pediatric Philadelphia (Ph)-like acute lymphoblastic leukemia.

More Research Required to Advance Pediatric Ph-Like ALL Paradigm

October 22nd 2018

Sarah K. Tasian, MD, discusses the diagnostic and therapeutic approaches to treating patients with pediatric Philadelphia-like acute lymphoblastic leukemia.

Dr. Crompton on Challenges With Liquid Biopsies in Pediatric Sarcoma

October 22nd 2018

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the challenges associated with implementing liquid biopsies in pediatric sarcoma.

Identification of Combinations For Pediatric Rhabdomyosarcomas

October 22nd 2018

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses a study analyzing effective combinations with regorafenib for the treatment of pediatric rhabdomyosarcomas.

Dr. Tasian on Frontline Therapy for Pediatric Patients With Ph-Like ALL

October 18th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia (CHOP), discusses frontline therapy for pediatric patients with Ph-like acute lymphoblastic leukemia (ALL).

Next Steps With the St. Jude Lifetime Cohort Study

October 17th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the next steps of the St. Jude Lifetime Cohort Study.

Dr. Upadhyaya on Outcomes for Children on the SJYC07 Trial

October 12th 2018

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses outcomes for children enrolled on the SJYC07 trial.

Dr. Tasian on Genetic Testing in Pediatric ALL

October 10th 2018

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses genetic testing in pediatric acute lymphoblastic leukemia.